Expression of Helicobacter pylori hspA Gene in Lactococcus lactis NICE System and Experimental Study on Its Immunoreactivity

Abstract EN

Aim.

The aim of this study was to develop an oral Lactococcus lactis (L.

lactis) vaccine against Helicobacter pylori (H.

pylori).

Methods.

After L.

lactis NZ3900/pNZ8110-hspA was constructed, growth curves were plotted to study whether the growth of recombinant L.

lactis was affected after hspA was cloned into L.

lactis and whether the growth of empty bacteria, empty plasmid bacteria, and recombinant L.

lactis was affected by different concentrations of Nisin; SDS-PAGE and Western blot were adopted, respectively, to detect the HspA expressed by recombinant L.

lactis and its immunoreactivity.

Results.

There was no effect observed from the growth curve after exogenous gene hspA was cloned into L.

lactis NZ3900; different concentrations of Nisin did not affect the growth of NZ3900 and NZ3900/pNZ8110, while different concentrations of Nisin inhibited the growth of NZ3900/pNZ8110-hspA except 10 ng/mL Nisin.

No HspA strip was observed from SDS-PAGE.

Western blot analysis showed that HspA expressed by recombinant bacteria had favorable immunoreactivity.

Conclusion.

The growth of recombinant L.

lactis was suppressed even though a small amount of HspA had been induced to express.

Therefore recombinant L.

lactis only express HspA which was not suitable to be oral vaccine against Helicobacter pylori.